Results Obtained up to the Time of Completion of Post-Marketing Surveillance for Re-Examination: Out of a total 11,866 patients, 298 patients (2.51%) presented adverse reactions. The primary reactions were 100 cases of vomiting (0.84%), 55 cases of feeling of enlarged abdomen (0.46%), 54 cases of retching (0.46%), 40 cases of feeling cold (0.34%), 37 cases of nausea (0.31%), etc. Anomaly of laboratory findings was seen in 157 patients (1.32%) or 224 cases. The primary ones were 28 cases of positive urine ketone bodies (0.24%), 22 cases of increased GOT (0.19%), 22 cases of increased GPT (0.19%) and 16 cases of increased LDH (0.13%).
Results of a Controlled Study Dedicated to the Addition of the Previous-Day Dosing Method: Out of a total 147 dosed patients, 130 patients (88.4%) (including anomaly of laboratory findings) presented adverse reactions. The primary ones were 92 cases of feeling of enlarged abdomen (62.6%), 52 cases of nausea (35.4%), 34 cases of abdominal pain (23.1%), 40 cases of feeling cold (27.2%), 20 cases of malaise (13.6%), 15 cases of dizziness (10.2%), 9 cases of vomiting (6.1%), 7 cases of headache (4.8%), 6 cases of sleep loss (appeared only in the previous-day dosing method) (4.1%), 6 cases of increased bilirubin value (4.1%), 4 cases of increased GOT (2.7%), 2 cases of increased GPT (1.4%), etc. It should be noted that in this study, all subjective and objective symptoms with which causal relationship of Niflec cannot be denied were included in the category of adverse reactions.
Clinically Significant Adverse Reactions: Shock, Anaphylactoid Symptoms: Since shock and anaphylactoid symptoms may occur, close monitoring should be carried out. When facial pallor, decreased blood pressure, vomiting, continuous nausea, feeling bad, vertigo, feeling cold, urticaria, dyspnea, face oedema and so forth arise, administration should be discontinued and adequate treatment should be given. In cases where patients are allowed to take Niflec at home, it is necessary to offer them guidance by referring to Important Basic Precautions under Precautions.
Intestinal Perforation: Since intestinal perforation may occur, close monitoring should be carried out. When anomaly is observed, administration should be discontinued and adequate treatment should be given. In cases where patients are allowed to take Niflec at home, it is necessary to offer them guidance by referring to Important Basic Precautions under Precautions.
Hyponatraemia: Since vomiting may cause hyponatraemia which can lead to disturbed consciousness, convulsion, etc, adequate treatment should be given (eg, correction of electrolyte) when such symptoms arise. In cases where patients are allowed to take the drug at home, it is necessary to offer them guidance by referring to Important Basic Precautions under Precautions.
Others: See Table 3.
Click on icon to see table/diagram/image